<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8">
  <meta http-equiv="X-UA-Compatible" content="IE=edge">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <link rel="shortcut icon" href="../images/favicon.png" type="image/x-icon">
  <title>Anticoagulants</title>
  <link href="https://cdn.jsdelivr.net/npm/remixicon@2.5.0/fonts/remixicon.css" rel="stylesheet">
  <link rel="stylesheet" href="../style.css">
  <link rel="stylesheet" href="../notes.css">

</head>
<body>
  <input type="checkbox" id="main-navigation-toggle" class="btn btn--close" title="Toggle main navigation" />
  <label for="main-navigation-toggle">
    <span></span>
  </label>
  
  <a href="../index.html">
   <div class="home-navigation">
      mtr<span class="logo-dot">.</span>
    </div>
  </a>


    <nav id="main-navigation" class="nav-main">
    <ul class="menu">
      <li class="menu__item">
        <a class="menu__link" href="../index.html">Home</a>
      </li>

      <li class="menu__item">
        <a class="menu__link" href="../about-temp2.html">About</a>
      </li>
    </ul>
  </nav>
  
      <!-- Toggle switch for dark mode -->
      <div class="dark-mode-toggle">
        <label class="switch-toggle">
            <input type="checkbox" id="dark-mode-toggle-checkbox">
            <span class="toggle-slider"></span>
        </label>
      </div>

      <!-- Progress Bar  -->
      <div id="progress-container">
        <div id="progress-bar"></div>
    </div>
      
<!-- SIDEBAR -->
<div id="sidebar" class="sidebar">
  <button id="closeSidebarBtn" class="btn toggle-btn close-btn">Close</button>
  <ul class="sidebar-menu toggle-menu">
    <!-- Add the list of topics dynamically using JavaScript -->
  </ul>
</div>

<!-- Toggle button to open the sidebar -->
<button id="toggleSidebarBtn" class="btn toggle-btn">&#9776;</button>

<!-- END OF SIDEBAR -->

  <main class="page-container">
    <div class="contribute-cta">
      <p>Help make this betterüíú</p>
      <span><a href="../contribute.html">Contribute here</a> </span>
    </div>


  <!-- TOPIC AND IMAGE CONTAINER  -->

      <h1>Anticoagulants</h1>


  <!-- END OF TOPIC AND IMAGE CONTAINER  -->
  


    <article class="notes">
        <a id='top'></a>
    <article>

          <!-- LEARNING OBJECTIVES CONTAINER  -->
              <div class="custom-card" id="custom-card-1">
                <div class="icon"><img src="../images/icons/light-bulb.png" alt="Icon" class="icon"></div>
                <div class="title"> 
                  <h2>What You Will Learn</h2>
                </div>
                <div class="line">
                  <p>After reading this note, you should be able to...</p>
                </div>
                <div class="content">
                  <ul>
                    <li><i>This content is not available yet.</i></li>
                </ul>
                </div>
                <div class="read-more" onclick="toggleContent('custom-card-1')">Read More üç™</div>
              </div>
            
          <!-- END OF LEARNING OBJECTIVES CONTAINER  -->
        
        
          <!-- SHOW AND HIDE OUTLINE CONTAINER  -->
            <div class="outline2">
        
              <input type="radio" name="control-2" id="show-2">
              <label for="show-2">üêµ&nbsp; &nbsp;Show Outline</label>
              <input type="radio" name="control-2" id="hide-2">
              <label for="hide-2">üôà&nbsp; &nbsp; Hide Outline</label>
              <div class="contents">
                <div class="icon-box">
                  <!-- Replace 'path/to/your/icon.png' with the actual path to your PNG icon -->
                  <img src="../images/icons/book.png" alt="Icon" class="icon">
                </div>
                <div id="tableOfContents">
                    <ol id="tocList"></ol>
                </div>
              </div>
             <div>
        
        <!-- END OF SHOW AND HIDE OUTLINE CONTAINER  -->
        
        
        <!-- READ SUMMARY CONTAINER -->
        
              <!-- Summary Overlay -->
              <div class="summary-overlay" id="summaryOverlay"></div>
        
        
              <div class="summary-card" id="summaryCard">
                
                <div class="summary-header">
                  <h3>Note Summary</h3>
                  <div class="icon-box">
                    <!-- Replace 'path/to/your/icon.png' with the actual path to your PNG icon -->
                    <img src="../images/icons/summary.png" alt="Icon" class="icon">
                  </div>
                </div>
                <div class="summary-content">
                  <!-- Summary content goes here -->
                  <p><i>This content is not available yet.</i></p>
        
                  <span class="close-btn" id="closeBtn">close</span>
                </div>
              </div>
        
              <div class="summary-trigger" id="summaryTrigger">
                <p>Click here to read a summary</p>
            </div>
        <!-- END OF READ SUMMARY CONTAINER -->
        
            <!-- BEGINNING OF NOTE -->
        
      <section id='header-1'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-1'>Introduction</a>
          </h2>
        </header>
        <div class='body'>
            <h4>GENERAL OVERVIEW</h4>
            <p><strong>Drugs</strong> that help prevent the <strong>clotting (coagulation)</strong> of blood. Coagulation will occur <strong>instantaneously</strong> once a blood vessel has been severed.</p>
            

            <h4>BLOOD CLOTTING</h4>
            <p><strong>Vascular Phase:</strong> After initial injury, a brief period of arteriolar vasoconstriction occurs, as a result of reflex neurogenic mechanisms augmented by the local secretion of factors such as endothelin (a potent endothelium-derived vasoconstrictor). The effect is transient.</p>
            
            <p><strong>Platelet Phase:</strong> Blood vessel wall (endothelial cells) prevent platelet adhesion and aggregation. Platelets contain receptors for fibrinogen and von-Willebrand factor. After vessel injury, platelets adhere and aggregate, releasing permeability-increasing factors (e.g., vascular permeability factor, VPF), losing their membrane, and forming a viscous plug.</p>
            
            <p><strong>Coagulation Phase:</strong> Two major pathways: Intrinsic pathway and Extrinsic pathway, both converge at a common point. Thirteen soluble factors are involved in clotting. Biosynthesis of some factors is dependent on Vitamin K. Normally inactive and sequentially activated.</p>

            <h4>FIBRINOLYSIS</h4>
            <p><strong>Enhance degradation</strong> of clots. Activation of endogenous protease. Plasminogen (inactive form) is converted to plasmin (active form). Plasmin breaks down fibrin clots.</p>
            
            
        </div>
      </section>

      <section id='header-2'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-2'>Cclassification</a>
          </h2>
        </header>
        <div class='body'>
            <p><strong>A. Parenteral Anti-Coagulants</strong></p>
            <ol>
              <li><strong>Indirect Thrombin Inhibitors</strong>
                <ol type="a">
                  <li> Heparins
                    <ol type="i">
                      <li> High Molecular Weight Heparin - Unfractionated Heparin (UFH)</li>
                      <li> Low Molecular Weight Heparins
                        <ul>
                          <li>Enoxaparin</li>
                          <li>Dalteparin</li>
                          <li>Tinzaparin</li>
                          <li>Reviparin</li>
                          <li>Danaparoid</li>
                        </ul>
                      </li>
                    </ol>
                  </li>
                </ol>
              </li>
              <li>
                <strong>Direct Thrombin Inhibitors</strong>
                <ul>
                    <li>Hirudin</li>
                    <li>Bivalirudin</li>
                    <li>Lepirudin</li>
                    <li>Argatroban</li>
                </ul>
              </li>
            </ol>
            
            <p><strong>B. Oral Anti-Coagulants</strong></p>
            <ol>
              <li>Coumarins
                <ul>
                  <li>Warfarin</li>
                  <li>Dicumarol</li>
                </ul>
              </li>
              <li>Indanediones
                <ul>
                  <li>Phenindione</li>
                </ul>
              </li>
            </ol>
            
            <p><strong>C. NEW ORAL ANTICOAGULANTS</strong></p>
            <ul>
              <li>Dabigatran</li>
              <li>Rivaroxaban</li>
              <li>Apixaban</li>
              <li>Endoxaban</li>
              <li>Betrixaban</li>
            </ul>
            

        </div>
      </section>

      <section id='header-3'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-3'>Heparin</a>
          </h2>
        </header>
        <div class='body'>
            <p>It is a mixture of straight chain anionic (negative charge) glycosaminoglycan with a wide range of molecular weights. It is strongly acidic because of the presence of sulfate and carboxylic acid groups. Commercial heparin is extracted from porcine intestinal mucosa and bovine lung.</p>

            <h4>PHARMACOKINETICS</h4>
            <p>Half-life: <strong>1 to 1.5 hours</strong>. Heparin is highly charged, thus crosses cell membranes very poorly, hence given <strong>Parenterally</strong>.</p>
            <p><strong>Dose:</strong>
              <ul>
                <li>Bolus: <strong>80 units/kg</strong> or <strong>5000 units</strong></li>
                <li>Maintenance: <strong>15 units/kg/hr</strong> or <strong>700 to 2000 units/day</strong></li>
              </ul>
            </p>
            <p>Low dose: <strong>Subcutaneous</strong>. High Dose: <strong>Subcutaneous or IV Injection</strong>. Metabolized by liver, half-life depends on dose.</p>
            
            <h4>MECHANISM OF ACTION</h4>
            <p>Activated factors IXa, Xa, XIa, XIIa, and IIa are neutralized by Anti-thrombin III (AT III). Heparin accelerates the interaction of the active clotting factors with ATIII. Once the antithrombin-clotting factor complex is formed, heparin is released for renewed binding to more antithrombin.</p>
            
            <p>High molecular weight Heparins accelerate the inactivation of clotting factors IIa and Xa. Low molecular weight heparins accelerate the inactivation of only Factor Xa.</p>
            

            <h4>MONITORING HEPARIN</h4>
            <p>Activated Partial Thromboplastin Time (aPTT)<br> Normal range: <strong>25-40 seconds</strong><br> Therapeutic Range: <strong>55-70 seconds</strong><br> Timing: 4-6 hours after commencing infusion, 4-6 hours after changing dosing regimen.</p>
            
            <section id='heading-3-1'>
                <header>
                  <h3>
                    <a aria-hidden href='#heading-3-1'>Low Molecular Weight Heparin</a>
                  </h3>
                </header>
                <div class='body'>
                    <p>Mechanism of action: Inhibit clotting factor Xa more than IIa.</p>
                    <p>Examples:</p>
                    <ul>
                      <li>Dalteparin</li>
                      <li>Enoxaparin</li>
                      <li>Tinzaparin</li>
                    </ul>
                    
                    <p>Half-life: <strong>3 to 4 times than Heparin</strong>.</p>
                    <p>Doses:</p>
                    <ul>
                      <li>Dalteparin: <strong>2500-5000 units/day</strong></li>
                      <li>Enoxaparin: <strong>30-40 mg/day</strong></li>
                      <li>Tinzaparin: <strong>175 units/day</strong></li>
                    </ul>
                    
                    <h4>ADVANTAGES OF LMWH OVER UFH</h4>
                    <ul>
                      <li>Better subcutaneous bioavailability (70-90%) compared to UFH (20-30%).</li>
                      <li>Longer and more consistent half-life: once daily subcutaneous administration.</li>
                      <li>Since aPTT/clotting times are not prolonged, lab monitoring is not needed.</li>
                      <li>Lower incidence of hemorrhagic complications.</li>
                    </ul>
                    
                </div>
              </section>

              <section id='heading-3-2'>
                <header>
                  <h3>
                    <a aria-hidden href='#heading-3-2'>Uses of Heparin</a>
                  </h3>
                </header>
                <div class='body'>
                    <ol>
                      <li>Treatment & Prevention of Deep Venous Thrombosis in:
                        <ul>
                          <li>Bedridden (Immobilized patients)</li>
                          <li>Old people</li>
                          <li>Post-operative</li>
                          <li>Post-stroke patients</li>
                          <li>Leg fractures</li>
                          <li>Elective Surgery</li>
                        </ul>
                      </li>
                      <li>Ischemic Heart Disease:
                        <ul>
                          <li>Unstable angina</li>
                          <li>After MI</li>
                          <li>After angioplasty</li>
                          <li>CABG, stent replacement</li>
                        </ul>
                      </li>
                      <li>Rheumatic Heart Disease/Atrial Fibrillation</li>
                      <li>Cerebrovascular Diseases:
                        <ul>
                          <li>Cerebral Emboli (Prevention of recurrence)</li>
                        </ul>
                      </li>
                      <li>Vascular Surgery, Prosthetic heart valves, Hemodialysis:
                        <ul>
                          <li>To prevent thromboembolism</li>
                        </ul>
                      </li>
                      <li>DIC:
                        <ul>
                          <li>Abruptio placenta, malignancies, infections; increased consumption of clotting factors</li>
                        </ul>
                      </li>
                    </ol>
                    
    
                </div>
              </section>

              <section id='heading-3-3'>
                <header>
                  <h3>
                    <a aria-hidden href='#heading-3-3'>Adverse Effects</a>
                  </h3>
                </header>
                <div class='body'>
                    <ol>
                      <li>Bleeding (most common)</li>
                      <li>Allergy and Anaphylaxis</li>
                      <li>Increased hair loss, alopecia</li>
                      <li>Long term - Osteoporosis, spontaneous fractures</li>
                      <li>Thrombocytopenia</li>
                    </ol>
                    

                    
    
                </div>
              </section>

              <section id='heading-3-4'>
                <header>
                  <h3>
                    <a aria-hidden href='#heading-3-4'>Contraindications</a>
                  </h3>
                </header>
                <div class='body'>
                    <ol>
                      <li>Hypersensitivity</li>
                      <li>Bleeding Disorders like Hemophilia</li>
                      <li>Thrombocytopenia</li>
                      <li>Intracranial Hemorrhage</li>
                      <li>GIT Ulcerations</li>
                      <li>Threatened abortion</li>
                      <li>Advanced renal or hepatic disease</li>
                    </ol>
    
                </div>
              </section>

              
              <section id='heading-3-5'>
                <header>
                  <h3>
                    <a aria-hidden href='#heading-3-5'>Heparin and Pregnancy</a>
                  </h3>
                </header>
                <div class='body'>
                    <p>Heparin does not cross the placenta, therefore it must be used instead of warfarin in cases requiring anticoagulant therapy during pregnancy. Warfarin crosses the placenta and induces changes in the fetus to produce the fetal warfarin syndrome.</p>
                    
    
                </div>
              </section>

              
              <section id='heading-3-6'>
                <header>
                  <h3>
                    <a aria-hidden href='#heading-3-6'> Heparin Induced Thrombocytopenia (HIT)</a>
                  </h3>
                </header>
                <div class='body'>
                    <h4> </h4>
                    <ul>
                      <li>2nd most common side effect after bleeding.</li>
                      <li>Occurs in 3-5% of patients 5 to 10 days after initiation of standard heparin therapy.</li>
                      <li>Lower incidence in low molecular wt. heparin.</li>
                      <li>Can be life-threatening.</li>
                      <li>Due to production of IgG against complexes of heparin with platelet.</li>
                      <li>The complexes activate more platelets with the release of more platelet factor 4 or other cytokines.</li>
                      <li>This stimulates the formation of more IgG.</li>
                      <li>This snowball effect uses up platelets and also leads to thrombosis. Systemic bleeding and localized infarction (due to thrombosis) occur.</li>
                      <li>Once thrombocytopenia is determined, heparin must be stopped. Direct thrombin inhibitor should be given.</li>
                      <li>Platelets must NOT be given because they will react with antibody already being produced against them, causing a greater chance of thrombosis.</li>
                    </ul>
                    
    
                </div>
              </section>
            
              <section id='heading-3-7'>
                <header>
                  <h3>
                    <a aria-hidden href='#heading-3-7'>Antidote- Protamine Sulfate</a>
                  </h3>
                </header>
                <div class='body'>
                    <p>Protamine is a highly basic peptide that combines with heparin as an ion pair to form a stable complex devoid of anticoagulant activity.</p>
                    <p>Hemorrhage can be reversed by protamine sulfate titrated so that 1 mg of protamine sulfate is administered for every 100 U of heparin. Protamine sulfate is also an anticoagulant because it interacts with platelets, fibrinogen, and other clotting factors ‚Äì so it can make hemorrhage worse if more is given than necessary.</p>
                    
    
                </div>
              </section>
        </div>
      </section>

      <section id='header-4'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-4'>Warfarin</a>
          </h2>
        </header>
        <div class='body'>
            <p>Wisconsin Alumni Research Foundation Coumarin</p>

            <h4>PHARMACOKINETICS</h4>
            <ol>
              <li>Rapidly and completely absorbed after oral administration</li>
              <li>100% Bioavailability</li>
              <li>Highly plasma protein bound (99%)</li>
              <li>Crosses the placenta (teratogenic)</li>
              <li>Appears in milk</li>
              <li>Variable but slow clearance; depends on hepatic cytochrome P450s</li>
              <li>Biotransformation by the liver: Oxidation, Glucuronidation</li>
              <li>Half-life: 40 hours</li>
              <li>Doses: 2-15mg/day</li>
              <li>Monitoring: PT and INR</li>
            </ol>
            

            
            <h4>WARFARIN MECHANISM OF ACTION</h4>
            <ul>
                <li>Antagonism of Vitamin K</li>
                <li>No Synthesis of Functional Coagulation Factors</li>
                <ul>
                    <li>Factors VII IX X II</li>
                </ul>
              </ul>
            
              <h4>USES</h4>
              <ul>
                <li>Same as Heparin and other Anticoagulants.</li>
                <li>Monitoring necessary because of its low therapeutic index.</li>
                <li>PT (Prothrombin time is noted; time taken for blood to clot).</li>
                <li>Patients on Heparin are shifted to oral warfarin after 3-5 days.</li>
              </ul>
              
              <h4>ADVERSE EFFECTS</h4>
              <ol>
                <li>Bleeding: Most common and most serious adverse effect; Epistaxis, hematuria, GIT bleeding, internal hemorrhages</li>
                <li>Cutaneous Necrosis: This is due to decreased activity of Protein C. Protein C and Protein S found in bone & other tissues also require Gamma carboxylations</li>
                <li>Infarction of breast, fatty tissues, intestine, and extremities due to venous thrombosis caused by again decreased activity of Protein C</li>
              </ol>
              
              <h4>ANTIDOTE OF WARFARIN</h4>
              <ul>
                <li>Stop Warfarin</li>
                <li>Give Vitamin K (Antidote)</li>
                <li>Also Fresh frozen plasma, Prothrombin complex concentrates, and Recombinant factor VIIa can be administered.</li>
              </ul>
              
              <h4>CONTRAINDICATIONS</h4>
              <ol>
                <li>
                  <p>Pregnancy:</p>
                  <ul>
                    <li>Fetal protein in bone and blood affected - Causes birth defects including abnormal bone formation, bone hypoplasia.</li>
                    <li>CNS defects, fetal hemorrhage, fetal hypoprothrombinemia, and fetal death may occur.</li>
                  </ul>
                </li>
                <li>Other contraindications same as heparin.</li>
              </ol>
              

              <h4>PHYSIOLOGICAL/PATHOLOGICAL FACTORS AFFECTING WARFARIN ACTION</h4>
              <ol>
                <li>
                  <p>Increased warfarin action</p>
                  <ul>
                    <li>Malnutrition, debility (Decreased Vit. K)</li>
                    <li>Liver disease, chronic alcoholism (Decreased clotting factors)</li>
                    <li>Hyperthyroidism (Increased degradation of Clotting factors)</li>
                    <li>Newborns (Decreased vitamin K)</li>
                  </ul>
                </li>
                <li>
                  <p>Decreased Warfarin Action</p>
                  <ul>
                    <li>Pregnancy (Increased clotting factors)</li>
                    <li>Nephrotic syndrome</li>
                    <li>Warfarin resistance (Genetic)</li>
                  </ul>
                </li>
              </ol>

              <h4>Stopping warfarin before operation</h4>
              <ul>
                <li>
                  Check INR:
                  <ul>
                    <li>INR 2-3: discontinue warfarin 5 days before operation</li>
                    <li>INR 3-4.5: discontinue 6 days before operation</li>
                    <li>Target preop. INR < 1.2</li>
                    <li>Elderly associated with a slower rate of decrease in INR</li>
                    <li>If INR > 1.5 (1-2 days before surgery) to give 1-2 mg oral vitamin K</li>
                    <li>Warfarin need not be stopped for all procedures</li>
                  </ul>
                </li>
              </ul>
              
              <h4>Starting heparin before the operation</h4>
              <p>Assessment of the patient which requires bridging therapy based on individual risk factors</p>
              <p>Recommendation for peroperative bridge therapy:</p>
              <ul>
                <li>High-risk group: bridging anticoagulation with therapeutic dose of subcutaneous LMWH/intravenous UFH</li>
                <li>Moderate-risk group: therapeutic dose of LMWH/UFH or low dose subcutaneous LMWH</li>
                <li>Low risk: low dose subcutaneous LMWH or no bridging</li>
              </ul>
              
              <h4>After surgery</h4>
              <ul>
                <li>Minor surgery (high-risk group):
                  <ul>
                    <li>Reinitiate LMWH at full dose 24 hours after surgery</li>
                  </ul>
                </li>
                <li>Major surgery/high risk of bleeding:
                  <ul>
                    <li>Use prophylactic dose on the first 2 postoperative days then full dose of LMWH OR</li>
                    <li>Delay the initiation of therapeutic dose for 48-72 hours postoperatively.</li>
                  </ul>
                </li>
              </ul>
              
              <p>Discuss with surgeon regarding reinitiation of anticoagulant.</p>
              <ul>
                <li>Restart warfarin as previous dose 1 day post-op (12-24 hours) when hemostasis is adequate.</li>
                <li>Daily PT/INR till discharge and periodically after discharge till INR reaches therapeutic range.</li>
                <li>Discontinue LMWH when INR is between 2-3 for 2 consecutive days.</li>
              </ul>
              
        </div>
      </section>

      <section id='header-5'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-5'>Direct Thrombin Inhibitors (DTIs)</a>
          </h2>
        </header>
        <div class='body'>
            <p>The DTIs bind thrombin without additional binding proteins, such as antithrombin, and they do not bind to other plasma proteins such as platelet factor 4. Hirudin and Bivalirudin bind at both the catalytic or active site of thrombin as well as at a substrate recognition site. Argatroban binds only at the thrombin active site.</p>
            
            <h4>LEPIRUDIN</h4>
            <ul>
              <li>Monitored by aPTT.</li>
              <li>Action independent of antithrombin.</li>
              <li>Used in thrombosis related to heparin-induced thrombocytopenia.</li>
              <li>No antidote.</li>
              <li>Adverse effect: Antibody formation against thrombin-lepirudin complex.</li>
            </ul>
            
            <h4>BIVALIRUDIN</h4>
            <ul>
              <li>Inhibits platelet activation.</li>
              <li>Used in percutaneous coronary angiography.</li>
            </ul>
            
            <h4>ARGATROBAN</h4>
            <ul>
              <li>Used in heparin-induced thrombocytopenia with or without thrombosis.</li>
              <li>Monitored by aPTT.</li>
              <li>Dose reduction in liver disease.</li>
            </ul>
            
        </div>
      </section>







      <hr style="margin: 3rem 0;">

      <!-- PRACTICE QUESTIONS CONTAINER -->

      <div class="custom-card" id="custom-card-2">
        <div class="icon"><img src="../images/icons/practice-questions.png" alt="Icon" class="icon"></div>
        <div class="title"> 
          <h2>Practice Questions</h2>
        </div>
        <div class="line">
          <p>Check how well you grasp the concepts by answering the following questions...</p>
        </div>
        <div class="content">
          <ol>
            <li><i>This content is not available yet.</i></li>
          </ol>
        </div>
        <div class="read-more" onclick="toggleContent('custom-card-2')">Read More üç™</div>
      </div>

      <!-- END OF PRACTICE QUESTIONS CONTAINER -->


      <!-- CONTACT- COMMENT AND CONTRIBUTORS CONTAINER -->
      <div class="contact">
        <div class="comment-container">
          <div class="comment-icon">
            <!-- Add your icon image here -->
            <img src="../images/icons/comment.png" alt="Comment Icon">
          </div>
          <div class="comment-text">
            <!-- Add your text here -->
            <p>Send your comments, corrections, explanations/clarifications and requests/suggestions </p>
          </div>
          <a href="https://chat.whatsapp.com/FtDdb6uEFYzBCnTnMgm2Z1" class="comment-button">
            here
            <img src="../images/icons/whatsapp.png" alt="Image Icon">
          </a>
        </div>

        <div class="contributors-container">

          <h2 class="contributors-header">Contributors</h2>
  
        <br>
            <div class="contributor-box">
                <img class="contributor-avatar" src="../images/icons/woman.png" alt="Contributor 1 Avatar">
                <div class="contributor-info">
                    <h3 class="contributor-name">Jane Smith</h3>
                    <p class="contributor-description">She is not a real contributor.</p>
                    <div class="social-links">
                        <a href="#" target="_blank" class="social-icon">
                            <img src="../images/icons/whatsapp.png" alt="Social Icon 1">
                        </a>
                        <a href="#" target="_blank" class="social-icon">
                            <img src="../images/icons/twitter.png" alt="Social Icon 2">
                        </a>
                    </div>
                </div>
            </div>
        
            <div class="contributor-box">
                <img class="contributor-avatar" src="../images/icons/man.png" alt="Contributor 2 Avatar">
                <div class="contributor-info">
                    <h3 class="contributor-name">John Doe</h3>
                    <p class="contributor-description">He is not a real contributor.</p>
                    <div class="social-links">
                      <a href="#" target="_blank" class="social-icon">
                        <img src="../images/icons/whatsapp.png" alt="Social Icon 1">
                    </a>
                    <a href="#" target="_blank" class="social-icon">
                        <img src="../images/icons/linkedin.png" alt="Social Icon 2">
                    </a>
                    </div>
                </div>
            </div>
        
        </div>
      </div>

            <!-- END OF CONTACT- COMMENT AND CONTRIBUTORS CONTAINER -->
    </article>
   </article>
   <div style="height: 300px;"></div>
  </main>

  <footer>
    <div class="footer-container">
        <div>
          <p id="popup-trigger">disclaimer</p>

          <!-- The pop-up dive content -->
          <div id="popup" class="popup">
            <p>The contents on this ‚Äòwebsite‚Äô are for educational purposes only. The creators and operators of this website make no warranties, express or implied, regarding the accuracy, currency, or completeness of the information provided on the website. They shall not be held responsible for any errors or omissions, or for any actions taken based on the information provided on this website.</p>
            <button class="popup-close" onclick="closePopup()">Close</button>
          </div>    
          <p><a href="../about-temp2.html">about</a> </p>   
          <p><a href="../contribute.html">contribute</a> </p>
          <p><a href="https://chat.whatsapp.com/FtDdb6uEFYzBCnTnMgm2Z1">say hiüëã</a> </p>
        </div>

        <div class="footer-beta">
          <p>thisisatestversion</p>
        </div>
    </div>
  </footer>
<!------------  SCROLL UP ----------->
<a href="#" class="scrollup" id="scroll-up"> 
  <i class="ri-arrow-up-fill scrollup__icon"></i>
</a>
<script src="../main.js"></script>
<script src="../modal.js"></script>
<script src="../notes-sidebar.js"></script>
</body>
</html>
 
